Axsome Therapeutics (AXSM) Prepaid Assets (2015 - 2026)
Axsome Therapeutics (AXSM) reported Prepaid Assets of $23.5 million for Q1 2026, up 46.95% on a YoY basis from $16.0 million in Q1 2025, and up 72.32% sequentially from $13.7 million in Q4 2025.
Axsome Therapeutics (AXSM) Prepaid Assets (2015 - 2026) Analysis & Trends
Axsome Therapeutics (AXSM) has 12 years of Prepaid Assets data on file, last reported at $23.5 million in Q1 2026.
- For the quarter ending Q1 2026, Prepaid Assets rose 46.95% year-over-year to $23.5 million; the trailing twelve-month figure through Mar 2026 stood at $23.5 million (up 46.95% YoY), and the FY2025 full-year result was $13.7 million, up 13.97% from the prior year.
- Prepaid Assets grew to $23.5 million in Q1 2026, from $13.7 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $23.5 million in Q1 2026 to a low of $2.1 million in Q1 2022.
- A 5-year average of $10.4 million and a median of $11.8 million in 2024 frame the typical range for Prepaid Assets.
- Across the five-year window, Prepaid Assets soared 6040.97% in 2022 and rose 13.97% in 2025, its largest moves.
- Tracing AXSM's Prepaid Assets over 5 years: stood at $2.8 million in 2022, then jumped by 191.8% to $8.1 million in 2023, then surged by 47.6% to $12.0 million in 2024, then advanced by 13.97% to $13.7 million in 2025, then soared by 72.32% to $23.5 million in 2026.
- Business Quant data shows AXSM's Prepaid Assets at $23.5 million in Q1 2026, $13.7 million in Q4 2025, and $19.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Axsome Therapeutics | 12.28 Bn | 11.98 Bn | 176.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.52 Mn |
| Dec 31, 2025 | 13.65 Mn |
| Sep 30, 2025 | 19.79 Mn |
| Jun 30, 2025 | 16.34 Mn |
| Mar 31, 2025 | 16.01 Mn |
| Dec 31, 2024 | 11.98 Mn |
| Sep 30, 2024 | 13.41 Mn |
| Jun 30, 2024 | 11.81 Mn |
| Mar 31, 2024 | 12.03 Mn |
| Dec 31, 2023 | 8.12 Mn |
| Sep 30, 2023 | 6.80 Mn |
| Jun 30, 2023 | 5.91 Mn |
| Mar 31, 2023 | 5.20 Mn |
| Dec 31, 2022 | 2.78 Mn |
| Sep 30, 2022 | 2.46 Mn |
| Jun 30, 2022 | 4.09 Mn |
| Mar 31, 2022 | 2.12 Mn |
| Dec 31, 2021 | 45,286.00 |
| Sep 30, 2021 | 401,302.00 |
| Jun 30, 2021 | 435,804.00 |